Short versus Standard Duration of Anticoagulation Using Rivaroxaban After Elective Primary Total Hip Replacement Surgery
Led by Prof. Stavros Konstantinides, MD · Updated on 2025-01-16
2932
Participants Needed
6
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to determine the best duration of blood-thinning medication after elective total hip arthroplasty THA to prevent blood clots. The study compares a shorter 10-day course versus the standard 35-day course of anticoagulation after hip replacement surgery. It focuses on patients eligible for early mobilization and evaluates whether the shorter treatment is as effective at preventing dangerous clots within 90 days after surgery.
The trial randomly assigns patients to one of two groups one receiving the anticoagulant rivaroxaban from day 3 to day 10 post-surgery followed by placebo until day 35, and the other receiving rivaroxaban continuously for 35 days. Both groups follow a standard enhanced recovery protocol with early mobilization after surgery. This double-blind study includes an initial two-day open-label anticoagulation period before randomization.
Participants will have follow-up visits on day 35 and day 90 after surgery to monitor for blood clots, bleeding events, and overall recovery. Researchers will assess outcomes including symptomatic deep vein thrombosis, pulmonary embolism, hospital stay length, joint function, and quality of life. Safety and any adverse events will be closely tracked during these visits to understand the benefits and risks of shorter anticoagulation treatment after hip replacement.
CONDITIONS
Brief Title
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
Research Team
N
Nadine Martin, Dr.
S
Susanne Fischer, M.Sc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Scheduled to undergo elective unilateral primary total hip arthroplasty
Eligible for perioperative management based on the enhanced recovery after surgery (ERAS) protocol
Baseline Timed Up and Go test scoring less than 20 seconds indicating good mobility
Ability to understand and comply with protocol requirements, including sufficient German language skills and ability to swallow capsules
Negative serum pregnancy test for women of childbearing potential at screening
Willingness of women of childbearing potential and men able to father a child to use effective birth control or abstain during study drug treatment and washout period
You will not qualify if you...
History of previous deep vein thrombosis or pulmonary embolism
Hip or lower limb fracture in the previous three months
Major surgery within the previous three months
Active metastatic cancer or cancer requiring chemotherapy or radiation
Active peptic ulcer disease, gastritis, or prior gastrointestinal bleeding
Obesity with body mass index over 40 kg/m2
Severe renal impairment (estimated glomerular filtration rate less than 30 ml/min)
Severe liver impairment (Child Pugh Class B or C)
Uncontrolled illness such as active infection, heart failure, uncontrolled hypertension, unstable angina, interstitial lung disease, serious gastrointestinal conditions, or psychiatric illness
Active or recent major bleeding or significant bleeding risk
Medical conditions preventing discharge within 6 days after surgery
Expected need for major surgery within 90 days after hip arthroplasty
Need for long-term anticoagulation therapy
Need for chronic antiplatelet therapy except low-dose aspirin or clopidogrel
Previous participation in this trial
Life expectancy less than 6 months
Participation in another interventional trial within 30 days prior to inclusion
Known hypersensitivity to the investigational drug or related compounds
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Up to 2 weeks or until discharge
Participants undergo elective unilateral primary total hip arthroplasty and initial post-surgery recovery following an enhanced recovery protocol.
Initial hospital stay including surgery and immediate post-operative assessments
Treatment
Duration - 35 days after surgery
Participants receive prophylactic anticoagulation with rivaroxaban starting on day 3 after surgery. The experimental arm receives rivaroxaban from day 3 to 10 followed by placebo from day 11 to 35, while the control arm continues rivaroxaban until day 35 after surgery.
Daily medication with assessments as per local protocol; follow-up visits may be scheduled
Follow-up
Duration - Up to 3 months after surgery
Participants are monitored for acute symptomatic or fatal venous thromboembolism and other safety outcomes for up to 3 months after surgery.
Follow-up visits for monitoring symptoms and safety assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Study of Movement and Sports Return Using Biomechanical Sensors After Total Hip Replacement Surgery
Comparing Digital Tele-rehabilitation and Standard Physical Therapy After Total Hip Arthroplasty to Improve Recovery and Patient Outcomes
Short versus Standard Duration of Anticoagulation Using Rivaroxaban After Elective Primary Total Hip Replacement Surgery
Post-Market Study of Exactech Hip Systems for Total Hip Replacement
Collecting Patient Data Before and After Surgery
Evaluating One-Year Follow-Up After Total Hip or Knee Replacement Surgery to Improve Care and Reduce Unnecessary Visits
Evaluating Rescue Supra-Inguinal Fascia Iliaca Block for Pain Relief After Total Hip Replacement Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.
Joshua J Jacobs, Michael A Mont, Kevin John Bozic...
Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function.
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.
David R Anderson, Gian Paolo Morgano, Carole Bennett...
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
S Schulman, C Kearon, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis